• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

源于巴雷特发育异常的食管腺癌:化疗后双原发及长期生存的病例报告

Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy.

作者信息

Vats Hemender S, Banerjee Tarit K, Resnick Jeffrey, Khan Qaseem

机构信息

Department of General Internal Medicine, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, WI 54449, USA.

出版信息

Clin Med Res. 2006 Sep;4(3):184-8. doi: 10.3121/cmr.4.3.184.

DOI:10.3121/cmr.4.3.184
PMID:16988098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1570486/
Abstract

A relatively young patient with chronic gastroesophageal reflux disease (GERD), obesity, smoking, and alcohol intake presented with widespread metastatic disease in lymph nodes, liver and lungs from a lower esophageal adenocarcinoma extending into the gastroesophageal junction associated with Barrett's mucosa and dysplasia.A complete response was achieved with six cycles of chemotherapy that sustained for more than 4 years without further recurrence. Unfortunately, there was presence of esophageal metaplasia after complete response which eventually converted to low to high grade dysplasia and ultimately to a second primary localized lower esophageal adenocarcinoma that was treated with thoracoabdominal esophagectomy and lymphadenectomy. No evidence of disease recurrence was seen 2 years later. The pathogenesis of a recent increase in the incidence of GERD, Barrett's esophagus and lower esophageal adenocarcinoma are discussed. Surgery, radiotherapy and combination chemotherapy are effective in the early stages leading to tumor shrinkage and prolongation of life and even cure in some cases. Lower esophageal adenocarcinoma is frequently associated with Barrett's high-grade dysplasia. Since there has been a dramatic increase in the incidence of Barrett's dysplasia, appropriate surveillance with upper gastrointestinal endoscopy and preventive strategies, such as the use of aspirin, cyclo-oxygenase II inhibitors and other nonsteroidal antiinflammatory drugs known to be chemopreventive agents against colon, esophagus, gastric and bladder cancers, need to be studied.

摘要

一名相对年轻的慢性胃食管反流病(GERD)患者,伴有肥胖、吸烟和饮酒史,因下食管腺癌延伸至胃食管交界处并伴有巴雷特黏膜和发育异常,出现了广泛的淋巴结、肝脏和肺部转移。通过六个周期的化疗实现了完全缓解,缓解持续了四年多且无进一步复发。不幸的是,完全缓解后出现了食管化生,最终转变为低级别至高级别发育异常,并最终发展为第二原发性局限性下食管腺癌,接受了胸腹联合食管切除术和淋巴结清扫术。两年后未见疾病复发迹象。文中讨论了近期GERD、巴雷特食管和下食管腺癌发病率上升的发病机制。手术、放疗和联合化疗在早期有效,可导致肿瘤缩小、延长生命,甚至在某些情况下实现治愈。下食管腺癌常与巴雷特高级别发育异常相关。由于巴雷特发育异常的发病率急剧上升,需要研究通过上消化道内镜进行适当监测以及采取预防策略,如使用阿司匹林、环氧化酶II抑制剂和其他已知对结肠癌、食管癌、胃癌和膀胱癌具有化学预防作用的非甾体抗炎药。

相似文献

1
Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy.源于巴雷特发育异常的食管腺癌:化疗后双原发及长期生存的病例报告
Clin Med Res. 2006 Sep;4(3):184-8. doi: 10.3121/cmr.4.3.184.
2
Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.食管裂孔疝大小、巴雷特食管长度以及胃酸反流的严重程度均为食管腺癌的危险因素。
Am J Gastroenterol. 2002 Aug;97(8):1930-6. doi: 10.1111/j.1572-0241.2002.05902.x.
3
Is Barrett's metaplasia the source of adenocarcinomas of the cardia?巴雷特化生是贲门腺癌的来源吗?
Arch Surg. 1994 Jun;129(6):609-14. doi: 10.1001/archsurg.1994.01420300051007.
4
Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.胃食管反流与巴雷特食管:通向食管腺癌的途径。
Updates Surg. 2018 Sep;70(3):339-342. doi: 10.1007/s13304-018-0564-y. Epub 2018 Jul 23.
5
Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.反流控制在巴雷特食管的管理中很重要:来自1830例患者回顾性队列研究的结果
Surg Endosc. 2015 Dec;29(12):3528-34. doi: 10.1007/s00464-015-4103-3. Epub 2015 Feb 13.
6
Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.基于巴雷特食管的存在及有症状的胃食管反流情况,食管腺癌对术前放化疗和手术的不同反应
Ann Thorac Surg. 2005 May;79(5):1716-23. doi: 10.1016/j.athoracsur.2004.10.026.
7
Risk factors in the development of esophageal adenocarcinoma.食管腺癌发展的危险因素。
Am J Gastroenterol. 2013 Feb;108(2):200-7. doi: 10.1038/ajg.2012.387. Epub 2012 Dec 18.
8
Risk factors, DNA damage, and disease progression in Barrett's esophagus.巴雷特食管的危险因素、DNA损伤与疾病进展
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5. doi: 10.1158/1055-9965.EPI-04-0509.
9
Radical esophageal resection for adenocarcinoma arising in Barrett's esophagus.针对巴雷特食管腺癌的根治性食管切除术。
Am J Surg. 1997 Sep;174(3):307-11. doi: 10.1016/s0002-9610(97)00107-4.
10
The diagnosis and management of Barrett's esophagus.巴雷特食管的诊断与管理
Adv Surg. 1999;33:29-68.

引用本文的文献

1
Can We Increase the Resection Rate by Minimally Invasive Approach? Experience from 100 Minimally Invasive Esophagectomies.我们能否通过微创方法提高切除率?来自100例微创食管切除术的经验。
J Oncol. 2019 Feb 24;2019:3809383. doi: 10.1155/2019/3809383. eCollection 2019.

本文引用的文献

1
Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach.远端食管和近端胃癌预防的相关概念
CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51. doi: 10.3322/canjclin.55.6.334.
2
Complex diseases in gastroenterology and hepatology: GERD, Barrett's, and esophageal adenocarcinoma.胃肠病学和肝病学中的复杂疾病:胃食管反流病、巴雷特食管和食管腺癌。
Clin Gastroenterol Hepatol. 2005 Jun;3(6):529-37. doi: 10.1016/s1542-3565(05)00248-x.
3
Advances in Barrett's esophagus and esophageal adenocarcinoma.巴雷特食管和食管腺癌的进展
Gastroenterology. 2005 May;128(6):1554-66. doi: 10.1053/j.gastro.2005.03.032.
4
Systemic treatment for oesophageal cancer.食管癌的全身治疗
Eur J Cancer. 2005 Mar;41(5):664-72. doi: 10.1016/j.ejca.2004.10.030. Epub 2005 Jan 8.
5
Combined modality therapy of esophageal cancer: changes in the standard of care?食管癌的综合治疗:治疗标准的变化?
Ann Surg Oncol. 2004 Jul;11(7):641-3. doi: 10.1245/ASO.2004.04.907. Epub 2004 Jun 14.
6
Multiple management modalities in esophageal cancer: combined modality management approaches.食管癌的多种管理模式:综合模式管理方法。
Oncologist. 2004;9(2):147-59. doi: 10.1634/theoncologist.9-2-147.
7
Therapeutic options for esophageal cancer.食管癌的治疗选择。
J Gastroenterol Hepatol. 2004 Jan;19(1):4-12. doi: 10.1111/j.1440-1746.2004.03154.x.
8
Oesophageal cancer: new developments in systemic therapy.食管癌:全身治疗的新进展
Cancer Treat Rev. 2003 Dec;29(6):525-32. doi: 10.1016/s0305-7372(03)00104-x.
9
Treatment response and prognosis of patients after recurrence of esophageal cancer.食管癌复发后患者的治疗反应与预后
Surgery. 2003 Jan;133(1):24-31. doi: 10.1067/msy.2003.31.
10
Treatment outcomes of resected esophageal cancer.食管癌切除术后的治疗结果。
Ann Surg. 2002 Sep;236(3):376-84; discussion 384-5. doi: 10.1097/00000658-200209000-00014.